MAGNETISMM-32
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- NCT06152575 ↗
- Recruiting
- Pfizer
- Focused
We haven't built an HCP commentary report on MAGNETISMM-32 (elranatamab, elotuzumab and 4 more in Multiple Myeloma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on MAGNETISMM-32 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A PHASE 3, OPEN-LABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB, POMALIDOMIDE, DEXAMETHASONE (EPd) OR POMALIDOMIDE, BORTEZOMIB, DEXAMETHASONE (PVd) OR CARFILZOMIB, DEXAMETHASONE (Kd) IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTI-CD38 DIRECTED THERAPY
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Multiple Myeloma
- Interventions
- Elranatamab; Elotuzumab; Pomalidomide; Dexamethasone; Bortezomib; Carfilzomib
- Arms
- Elranatamab · Experimental
- Investigator's Choice · Active comparator
- Enrollment
- 492 (estimated)
- Primary outcomes
- Progression free survival per International Myeloma Working Group criteria
- Sponsor
- Pfizer
- Start
- Feb 8, 2024
- Primary completion
- Aug 30, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT06152575 · updated Aug 24, 2026